278 related articles for article (PubMed ID: 26060285)
1. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
Siberry GK; Jacobson DL; Kalkwarf HJ; Wu JW; DiMeglio LA; Yogev R; Knapp KM; Wheeler JJ; Butler L; Hazra R; Miller TL; Seage GR; Van Dyke RB; Barr E; Davtyan M; Mofenson LM; Rich KC;
Clin Infect Dis; 2015 Sep; 61(6):996-1003. PubMed ID: 26060285
[TBL] [Abstract][Full Text] [Related]
2. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir Disoproxil Fumarate Use during Pregnancy and Infant Bone Health: the Tenofovir in Pregnancy Pilot Study.
Kourtis AP; Wiener J; Wang L; Fan B; Shepherd JA; Chen L; Liu W; Shepard C; Wang L; Wang A; Bulterys M
Pediatr Infect Dis J; 2018 Nov; 37(11):e264-e268. PubMed ID: 30067600
[TBL] [Abstract][Full Text] [Related]
4. Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.
Osorio LE; Boechat MI; Mirochnick M; Kumwenda N; Kreitchmann R; Emel L; Pinto J; Joao E; Santos B; Swenson M; George K; Sato P; Mofenson L; Nielsen-Saines K;
Pediatr Infect Dis J; 2017 Feb; 36(2):184-188. PubMed ID: 27798550
[TBL] [Abstract][Full Text] [Related]
5. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.
Ransom CE; Huo Y; Patel K; Scott GB; Watts HD; Williams P; Siberry GK; Livingston EG;
J Acquir Immune Defic Syndr; 2013 Dec; 64(4):374-81. PubMed ID: 24169122
[TBL] [Abstract][Full Text] [Related]
6. Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.
Pintye J; Langat A; Singa B; Kinuthia J; Odeny B; Katana A; Nganga L; John-Stewart G; McGrath CJ
Infect Dis Obstet Gynecol; 2015; 2015():276851. PubMed ID: 26823647
[TBL] [Abstract][Full Text] [Related]
7. Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants.
Seidel V; Weizsäcker K; Henrich W; Rancourt RC; Bührer C; Krüger R; Feiterna-Sperling C
Eur J Pediatr; 2020 Jan; 179(1):99-109. PubMed ID: 31659467
[TBL] [Abstract][Full Text] [Related]
8. Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.
Nachega JB; Uthman OA; Mofenson LM; Anderson JR; Kanters S; Renaud F; Ford N; Essajee S; Doherty MC; Mills EJ
J Acquir Immune Defic Syndr; 2017 Sep; 76(1):1-12. PubMed ID: 28291053
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Gibb DM; Kizito H; Russell EC; Chidziva E; Zalwango E; Nalumenya R; Spyer M; Tumukunde D; Nathoo K; Munderi P; Kyomugisha H; Hakim J; Grosskurth H; Gilks CF; Walker AS; Musoke P;
PLoS Med; 2012; 9(5):e1001217. PubMed ID: 22615543
[TBL] [Abstract][Full Text] [Related]
10. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Stranix-Chibanda L; Tierney C; Sebikari D; Aizire J; Dadabhai S; Zanga A; Mukwasi-Kahari C; Vhembo T; Violari A; Theron G; Moodley D; George K; Fan B; Sommer MJ; Browning R; Mofenson LM; Shepherd J; Nelson B; Fowler MG; Siberry GK;
PLoS One; 2021; 16(2):e0246272. PubMed ID: 33544759
[TBL] [Abstract][Full Text] [Related]
11. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
Siberry GK; Williams PL; Mendez H; Seage GR; Jacobson DL; Hazra R; Rich KC; Griner R; Tassiopoulos K; Kacanek D; Mofenson LM; Miller T; DiMeglio LA; Watts DH;
AIDS; 2012 Jun; 26(9):1151-9. PubMed ID: 22382151
[TBL] [Abstract][Full Text] [Related]
12. In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.
Jao J; Abrams EJ; Phillips T; Petro G; Zerbe A; Myer L
Clin Infect Dis; 2016 Jun; 62(12):1604-1609. PubMed ID: 27009251
[TBL] [Abstract][Full Text] [Related]
13. Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants.
Liotta G; Floridia M; Andreotti M; Jere H; Sagno JB; Marazzi MC; Buonomo E; Scarcella P; Mancinelli S; Vella S; Giuliano M; Palombi L
AIDS; 2016 Jan; 30(3):525-7. PubMed ID: 26765942
[TBL] [Abstract][Full Text] [Related]
14. Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa.
Nyemba DC; Kalk E; Madlala HP; Malaba TR; Slogrove AL; Davies MA; Boulle A; Myer L; Powis KM
BMC Pregnancy Childbirth; 2021 May; 21(1):354. PubMed ID: 33947351
[TBL] [Abstract][Full Text] [Related]
15. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
16. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
[TBL] [Abstract][Full Text] [Related]
17. Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate.
Wen WH; Chen HL; Shih TT; Wu JF; Ni YH; Lee CN; Zhao LL; Lai MW; Mu SC; Tung YC; Hsu HY; Chang MH;
J Hepatol; 2020 Jun; 72(6):1082-1087. PubMed ID: 32044401
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
Mofenson LM; Baggaley RC; Mameletzis I
AIDS; 2017 Jan; 31(2):213-232. PubMed ID: 27831952
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.
M le Roux S; Jao J; Brittain K; Phillips TK; Olatunbosun S; Ronan A; Zerbe A; Abrams EJ; Myer L
AIDS; 2017 Jan; 31(1):97-104. PubMed ID: 27898591
[TBL] [Abstract][Full Text] [Related]
20. Growth and Neurodevelopment Outcomes in HIV-, Tenofovir-, and Efavirenz-Exposed Breastfed Infants in the PMTCT Option B+ Program in Malawi.
Kapito-Tembo AP; Bauleni A; Wesevich A; Ongubo D; Hosseinipour MC; Dube Q; Mwale P; Corbett A; Mwapasa V; Phiri S
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):81-90. PubMed ID: 33027153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
